



## ASX ANNOUNCEMENT

10 January 2007

### First Implant at Hannover Medical Centre

On 4 January 2007, Hannover Medical Centre in Germany became the third hospital to implant HeartWare's HVAD<sup>TM</sup> left ventricular assist device. The HVAD<sup>TM</sup> was implanted in a 57 year old male patient suffering advanced heart failure. The procedure was completed quickly and without incident. The patient has been transferred from the intensive care unit and continues to recover well from the surgery.

Dr Martin Strüber, the Director of the Thoracic Transplant Program at the Hannover Medical Centre, commented:

*"We are very pleased with the results of our first HeartWare implant. The HVAD<sup>TM</sup> is the smallest full output device clinically available for long-term use. The pumps small size, placement above the diaphragm and innovative cannulation technique, significantly reduce the complexity of the surgical procedure and present clear and distinct clinical advantages. The implant procedure was short and the patient has recovered remarkably well. I expect this pump to play a significant role in expanding the use of ventricular assist devices as an option for the treatment of patients with advanced heart failure."*

To date, seven patients have undergone HeartWare HVAD<sup>TM</sup> implantation, including four at Vienna General Hospital, two at Royal Perth Hospital and one at Hannover Medical Centre. On a cumulative basis, these patients have been supported for more than 800 days. The pumps have performed exceptionally well and all patients have made excellent recoveries. Of the seven patients, all but the most recent recipients have been discharged from the hospital.

HeartWare Chief Executive Officer, Mr. Doug Godshall commented:

*"We are very pleased to welcome the Hannover team to the HeartWare trial. With seven implants across three centres, we are now well on the way towards completing our twenty patient international study. Given our exceptional early clinical results and the growing enthusiasm among clinicians, we expect to see a healthy acceleration in our implant numbers over coming weeks."*



## About HeartWare

HeartWare is developing a family of proprietary circulatory assist devices to treat patients with heart failure. HeartWare is currently running an international clinical trial for its lead product, the HVAD<sup>TM</sup> left ventricular assist device. With a volume of 45cc, the HVAD<sup>TM</sup> is the smallest “3rd generation” pump and the only full output device implantable routinely within the thoracic cavity.

HeartWare’s miniaturization platform allows the development of smaller devices, potentially implantable by minimally invasive surgical techniques. Pre-clinical studies are underway, at various stages, for a number of miniaturized devices, ranging from approximately one third to approximately one tenth the volume of the HVAD<sup>TM</sup>.

### For further information:

[www.heartware.com.au](http://www.heartware.com.au)

Howard Leibman

Director Corporate Development

HeartWare Limited

+61 2 8215 7604 / 0402 440644

### Media enquiries:

Stuart Barton

Gavin Anderson & Company

+61 2 9552 4499 / 0404 054 857